Risks, Benefits of Cangrelor Consistent in Angina, ACS

Share this content:
Risks, Benefits of Cangrelor Consistent in Angina, ACS
Risks, Benefits of Cangrelor Consistent in Angina, ACS

MONDAY, Oct. 3, 2016 (HealthDay News) -- For patients with stable angina (SA) or acute coronary syndrome (ACS), the benefits and risks of cangrelor are consistent, according to a study published in the Sept. 26 issue of JACC: Cardiovascular Interventions.

Jérémie Abtan, M.D., from the Hôpital Bichat in Paris, and colleagues examined the safety and efficacy of cangrelor in patients with SA or ACS. A total of 10,942 patients were included in the modified intention to treat population (6,358 patients had SA and 4,584 had ACS) and were randomized to periprocedural administration of cangrelor or clopidogrel.

The researchers found that cangrelor consistently reduced the primary end point (composite of death, myocardial infarction, ischemia-driven revascularization, or stent thrombosis at 48 hours) in SA and ACS (odds ratios, 0.83 [95 percent confidence interval (CI), 0.67 to 1.01] and 0.71 [95 percent CI, 0.52 to 0.96], respectively). Cangrelor also consistently reduced stent thrombosis (odds ratios, 0.55 [95 percent CI, 0.30 to 1.01] in SA and 0.67 [95 percent CI, 0.42 to 1.06] in ACS). Cangrelor had a similar impact on Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries severe-moderate bleeding (odds ratios, 1.49 [95 percent CI, 0.67 to 3.33] and 1.79 [95 percent CI, 0.79 to 4.07], respectively).

"The benefits and risks of cangrelor were consistent in patients with SA and ACS," the authors write.

Several authors disclosed financial ties to the pharmaceutical and medical device industries.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

60 Percent of Adults Report Adverse Childhood Experiences

>60 Percent of Adults Report Adverse Childhood Experiences

Higher ACE exposures for black, Hispanic, multiracial individuals, those with below high school education

Few Yogurt Products Qualify As Low-Sugar

Few Yogurt Products Qualify As Low-Sugar

Only two of 101 children's yogurt and fromage frais products had ≤5 g sugar/100 g of product

Allopurinol Dose Escalation for Gout Doesn't Improve Mortality

Allopurinol Dose Escalation for Gout Doesn't Improve Mortality

Linked to small increase in mortality; at 2 years, 31 percent of dose escalators achieved serum urate goal

is free, fast, and customized just for you!




Already a member?

Sign In Now »